Sunitinib does not acutely alter left ventricular systolic function, but induces diastolic dysfunction

Area of Science:

• Cardiovascular Science
• Oncology
• Pharmacology

Background:

• Cancer chemotherapies, particularly multi-targeted tyrosine kinase inhibitors like sunitinib, are associated with cardiovascular adverse events.
• The mechanisms underlying these drug-induced cardiovascular toxicities remain largely unknown.
• Predicting and managing these side effects is crucial for patient care in both oncology and cardiology.

Purpose of the Study:

• To investigate the electropharmacological effects of sunitinib in a canine model.
• To explore potential biomarkers for predicting sunitinib-induced cardiovascular adverse events.

Main Methods:

• Electrophysiological and hemodynamic assessments were performed in halothane-anesthetized dogs (n=5).
• Sunitinib was administered intravenously at doses of 0.01 and 0.1 mg/kg.
• Plasma cardiac enzyme levels, including cardiac troponin I, were measured.

Main Results:

• Sunitinib induced dose-related decreases in left ventricular pressure and prolonged isovolumic relaxation time.
• Elevated cardiac troponin I levels were observed 30-60 minutes post-high-dose sunitinib administration.
• Other cardiohemodynamic and electrophysiological variables, as well as other cardiac biomarkers, remained unaffected.

Conclusions:

• Cardiac diastolic function and cardiac troponin I levels are potential predictors of sunitinib-induced cardiovascular adverse events.
• Monitoring these parameters may aid in the early detection and management of sunitinib cardiotoxicity.